Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Complications

Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice

  1. Eleni Beli1,
  2. Yuanqing Yan2,
  3. Leni Moldovan3,
  4. Cristiano P. Vieira4,
  5. Ruli Gao5,
  6. Yaqian Duan6,
  7. Ram Prasad4,
  8. Ashay Bhatwadekar7,
  9. Fletcher A. White8,
  10. Steven D. Townsend9,
  11. Luisa Chan10,
  12. Caitlin N. Ryan10,
  13. Daniel Morton10,
  14. Emil G. Moldovan11,
  15. Fang-I Chu12,
  16. Gavin Y. Oudit13,
  17. Hartmut Derendorf14,
  18. Luciano Adorini15,
  19. Xiaoxin X. Wang16,
  20. Carmella Evans-Molina1,6,17,
  21. Raghavendra G. Mirmira1,6,17,
  22. Michael E. Boulton4,
  23. Mervin C. Yoder1,
  24. Qiuhong Li18,
  25. Moshe Levi16,
  26. Julia V. Busik19 and
  27. Maria B. Grant4⇑
  1. 1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN
  2. 2Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX
  3. 3Department of Surgery, Indiana University School of Medicine, Indianapolis, IN
  4. 4Department of Ophthalmology and Visual Sciences, University of Alabama, Birmingham, AL
  5. 5Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
  6. 6Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN
  7. 7Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
  8. 8Department of Anesthesia, Indiana University School of Medicine, Indianapolis, IN
  9. 9Department of Chemistry, Vanderbilt University, Nashville, TN
  10. 10Second Genome, Inc., San Francisco, CA
  11. 11Northeastern University, Boston, MA
  12. 12Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
  13. 13Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
  14. 14Department of Pharmaceutics, University of Florida, Gainesville, FL
  15. 15Intercept Pharmaceuticals, New York, NY
  16. 16Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC
  17. 17Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
  18. 18Department of Ophthalmology, University of Florida, Gainesville, FL
  19. 19Department of Physiology, Michigan State University, East Lansing, MI
  1. Corresponding author: Maria B. Grant, mariagrant{at}uabmc.edu.
  1. E.B. and Y.Y. contributed equally to the manuscript.

Diabetes 2018 Sep; 67(9): 1867-1879. https://doi.org/10.2337/db18-0158
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    IF feeding prolonged survival of db/db mice without improving glycemic control. A: Depiction of the experimental protocol with the treatment groups. Mice were put on IF diet at 4 months of age and were held on IF for 7 months. ZT represents zeitgeber time, i.e., time when the lights went on. B: Glycated hemoglobin levels in db/db-AL and db/db-IF mice were higher compared with db/m mice; however, IF did not correct glycated hemoglobin levels. Data represent means ± SEM (n = 6–39). *P < 0.05. C: db/db-AL had reduced survival compared with db/m mice. IF improved survival rate of db/db-IF mice compared with that of normal controls. *P < 0.05.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    IF reduced DR in db/db mice. A–D: Representative images of the trypsin-digested retinas from the four experimental groups: db/m AL (A), db/m IF (B), db/db AL (C), and db/db IF (D). Arrows indicate acellular capillaries. Scale bars: 10 μm. E: Enumeration of acellular capillaries per mm2 retinal area. Data represent means ± SEM (n = 10). *P < 0.05, one-way ANOVA. F: Enumeration of IBA-1+ cells per mm2 retinal area from immunofluorescence-stained retina cryosections. Data represent means ± SEM (n = 3). G: Enumeration of CD45+ cells per mm2 retinal area from immunofluorescence-stained retina cryosections. Data represent means ± SEM (n = 3–5). F and G: *P < 0.05, two-way ANOVA.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    IF resulted in distinct changes in the microbiota of db/db mice. A–C: β Diversity (presence/absence ordination): Dimensional reduction of the Jaccard distance on presence/absence OTU table, using the PCoA ordination method. A: db/m-AL (green circles) vs. db/db-AL (blue triangles) mice; samples separated along axis 2 according to sample type. B: db/m-AL (green triangles) vs. db/m-IF (feeding, red triangles; fasting, red circles) mice; samples separated along axis 2 according to type, which indicated that samples from IF and AL treatments have different incidences of OTUs. C: db/db-AL (blue triangles) vs. db/db-IF (feeding, purple triangles; fasting, purple circles) mice; samples separated along axis 1 according to type. Samples from db/db-AL mice had a smaller degree of variation in microbiome β diversity than db/db-IF samples. P = 0.001 in all comparisons; n = 5 mice/group. D: Principal component analysis (PCA) of microbiota. Relative abundance of bacteria present in at least 10% of the samples (n = 180) was used. Samples grouped by both disease (spheres, db/m; cubes, db/db) and treatment (blue, AL; red, IF) but less clearly by feeding/fasting within the IF groups. Note that the AL cohorts are closer to each other, whereas the IF cohorts were much further apart, suggesting bigger differences in the microbiomes of db/m-IF and db/db-IF mice. E: Relative proportions of the six most abundant phyla (the aggregate relative abundance for each of the phyla not represented here is less than 0.1). aP < 0.01 vs. db/m-AL; bP < 0.001 vs. db/m-AL; cP < 0.05 vs. db/db-AL; dP < 0.001 vs. db/db-AL; eP < 0.05 vs. db/m IF (feeding); fP < 0.001 vs. db/m IF (feeding); gP < 0.05 vs. db/db IF (fasting). All OTUs (detected in at least 10% of the samples) from all samples per each group were used, irrespective of zeitgeber time. p., phylum.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    IF effects on microbiome composition at the genus level. A: Genera that show statistically significant changes in db/db-AL vs. db/m-AL mice. B: Genera that were statistically different in db/db-IF vs. db/m-IF mice in the feeding phase. C: Genera that were statistically different in db/db-IF vs. db/m-IF in the fasting phase. Points are OTUs belonging to each respective genus. Features were considered significant if false discovery rate–corrected P value ≤0.05 and the absolute value of log2 fold change ≥1. D–O: Time course of relative bacterial abundances of selected taxa during the 48-h cycle of IF regimen are shown. ZT represents zeitgeber time, i.e., time when the lights went on. Diurnal oscillations in selected taxa and IF effects: o. Clostridiales (D), f. Ruminococcaceae (E), f. Lachnospiraceae (F), g. Lactobacillus (G), g. Bifidobacterium (H), g. Clostridium (I), g. Oscillospira (J), g. Ruminoccocus (K), g. Turicibacter (L), g. Bacteroides (M), g. Akkermansia (N), and g. Allobaculum (O). Data are sums of relative abundance of all OTUs within each genus ± SEM. f., family; g., genus; o., order.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    IF treatment affected gut morphology. A–D: Periodic acid Schiff (PAS) staining showing mucin-positive goblet cells. Diabetes reduced goblet cell number, but IF prevented this reduction. E: Quantification of goblet-positive cells. Data represent number of goblet cells/villus. *P < 0.05, n = 13–30 villi/group. F–I: Hematoxylin and eosin (H&E) staining of colon. The length of villi was reduced significantly with diabetes, but IF restored levels to normal. J: Quantification of the villi length, in pixels. *P < 0.05, n = 17–26 villi/group. K–N: Hematoxylin and eosin staining of the muscularis layer. O: Quantification of the muscularis width. Twenty measurements distributed evenly were done on each section, and data represent averages per section in pixels ± SD; n = 4–7 sections/group. In all cases, one section per mouse was analyzed. Scale bars: 50 μm. P: Peptidoglycan, a component of bacterial cell wall, was measured in plasma from the cohorts using ELISA. Data represent means ± SD (n = 3–5). *P < 0.05, two-way ANOVA.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    IF enhanced BA metabolism with increases in the neuroprotective BA TUCDA. Analysis of plasma samples for BA metabolites cholate (A), deoxycholate (B), TUDCA (C), and TCDCA (D). TCDCA and TUDCA were significantly increased with IF diet in the db/db-IF mice. TCDCA is converted to TUDCA by the actions of both 7α- and 7β-HSDH. Values for each sample are normalized by sample volume/utilized for extraction. Each biochemical is then scaled to set the median equal to 1. Missing values are imputed with the minimum. Data represent means ± SD (n = 4–6). *P < 0.05, two-way ANOVA.

  • Figure 7
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7

    TGR5 activation using the BA agonist INT-767 prevented DR. A: TGR5 immunofluorescence staining is located in the retinal ganglion cell layer of a db/m control mouse. NeuN is used as a marker of ganglion cells. TGR5: green, NeuN: red, and DAPI: blue. INL, inner nuclear layer; GCL, ganglion cell layer; ONL, outer nuclear layer. B–E: TGR5 and NeuN staining in db/m-AL (B), db/m-IF (C), db/db-AL (D), and db/db-IF (E). F: Quantification of the fluorescence intensity of TGR5 in the retinal ganglion cell layer. Data represent means ± SD (n = 10–12). G: TGR5 mRNA expression in retinas from all cohorts. Data represent means ± SD (n = 5–7). H: TNF-α mRNA expression in retinas from all cohorts. Data represent means ± SD (n = 4–5). *P < 0.05, two-way ANOVA. I–L: Effects of INT-767 on retinas of 20-week STZ-diabetic DBA/2J mice. I: INT-767 protects from development of DR as measured by enumeration of acellular capillaries. J: INT-767 returns CD45+ cell numbers to levels seen in no diabetic mice. K: Inflammatory monocytes are reduced in the INT-767–treated mice, as shown by quantification of CD11b+ cells. L: INT-767 reduced numbers of IBA-1+ cells within the retina. C, DBA/2J mice fed with vehicle; C+INT, DBA/2J mice fed with INT-767; D, STZ/WD mice; D+INT, STZ/WD with INT-767. Data represent means ± SD (n = 6 per group). *P < 0.05, one-way ANOVA.

  • Figure 8
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8

    A model for IF-induced changes in the microbiome and their potential impact on development of DR. In diabetic mice, IF resulted in significant expansion of bacteria of the Firmicutes phylum that metabolize primary BAs to secondary BAs, such as TUDCA. TUDCA then enters the circulation and crosses the blood-retina barrier, targets its receptor, TGR5, in the ganglion cell layer and protects against retinal neurodegeneration and inflammation.

PreviousNext
Back to top
Diabetes: 67 (9)

In this Issue

September 2018, 67(9)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice
Eleni Beli, Yuanqing Yan, Leni Moldovan, Cristiano P. Vieira, Ruli Gao, Yaqian Duan, Ram Prasad, Ashay Bhatwadekar, Fletcher A. White, Steven D. Townsend, Luisa Chan, Caitlin N. Ryan, Daniel Morton, Emil G. Moldovan, Fang-I Chu, Gavin Y. Oudit, Hartmut Derendorf, Luciano Adorini, Xiaoxin X. Wang, Carmella Evans-Molina, Raghavendra G. Mirmira, Michael E. Boulton, Mervin C. Yoder, Qiuhong Li, Moshe Levi, Julia V. Busik, Maria B. Grant
Diabetes Sep 2018, 67 (9) 1867-1879; DOI: 10.2337/db18-0158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice
Eleni Beli, Yuanqing Yan, Leni Moldovan, Cristiano P. Vieira, Ruli Gao, Yaqian Duan, Ram Prasad, Ashay Bhatwadekar, Fletcher A. White, Steven D. Townsend, Luisa Chan, Caitlin N. Ryan, Daniel Morton, Emil G. Moldovan, Fang-I Chu, Gavin Y. Oudit, Hartmut Derendorf, Luciano Adorini, Xiaoxin X. Wang, Carmella Evans-Molina, Raghavendra G. Mirmira, Michael E. Boulton, Mervin C. Yoder, Qiuhong Li, Moshe Levi, Julia V. Busik, Maria B. Grant
Diabetes Sep 2018, 67 (9) 1867-1879; DOI: 10.2337/db18-0158
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Discussion
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease
  • circRNA_010383 Acts as a Sponge for miR-135a, and Its Downregulated Expression Contributes to Renal Fibrosis in Diabetic Nephropathy
  • CaM Kinase II-δ Is Required for Diabetic Hyperglycemia and Retinopathy but Not Nephropathy
Show more Complications

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.